Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in oligodendrocytes (1142 nCPM) | 1.00 |
| chemistry Open Targets | compounds already reach it: pentoxifylline, dipyridamole | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 2 Parkinson's papers of 163 | 0.85 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
Knock down and overexpress PDE1A in oligodendrocytes; measure a transcriptome-wide state shift (bulk RNA-seq) and α-synuclein uptake and myelin basic protein output under oxidative stress.
- Cell type
- oligodendrocytes
- Direction
- Both arms: public data does not say which way helps; existing compounds already reach the inhibition arm.
- Molecular readout
- a transcriptome-wide state shift (bulk RNA-seq)
- Functional readout
- α-synuclein uptake and myelin basic protein output under oxidative stress
- Rule-out
- If neither arm moves a transcriptome-wide state shift (bulk RNA-seq) by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of PDE1A in iPSC-derived oligodendrocytes; n = 3 differentiations; readouts: a transcriptome-wide state shift (bulk RNA-seq); α-synuclein uptake and myelin basic protein output under oxidative stress. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- PDE1A in dopamine neurons, braak-0.37 (p 0.321) → +0.53 (p 0.140)receipt 3575
- PDE1A in oligodendrocytes, braak+0.55 (p 0.128) → +0.27 (p 0.487)receipt 3574
Swarm cases
receipt 3575: PDE1A in dopamine neurons, braak
- power
- full sample +0.15 (p 0.549, n 18), 95% CI -0.34 to +0.58. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.16 (p 0.532, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.24 (p 0.332, n 18). could be the mix.
- skeptic
- leave-one-out range +0.02 to +0.28, sign flips 0; without severely affected donors +0.15 (p 0.549, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PDE1A in dopamine neurons.
case closed: nothing better to follow up.
receipt 3574: PDE1A in oligodendrocytes, braak
- power
- full sample +0.33 (p 0.179, n 18), 95% CI -0.16 to +0.69. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.31 (p 0.211, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.35 (p 0.159, n 18). could be the mix.
- skeptic
- leave-one-out range +0.22 to +0.42, sign flips 0; without severely affected donors +0.33 (p 0.179, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PDE1A in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts